Scholars Central

Short communicationPublished 29 Aug 2025

Biosimilars: Cost Savings, Access, and Safe Integration

Authors: Dr. Peter Novak

Faculty of Pharmacy, Charles University, Czech Republic

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars are biological medicines demonstrating high similarity to reference products with no clinically meaningful differences in safety, purity, or potency. Their development pathways are designed for efficiency, offering cost savings and improved patient access. Keyconsiderationsincludeanalytical similarity, immunogenicity assessment, and pharmacovigilance. Economicbenefitsand regulatory frameworks, emphasizing a totality of evidence approach, drive adoption. Healthcare professional and patient acceptance, supported by real-world data, are crucial. Interchangeability is vital for market penetration, with evolving scientific and regulatory considerations

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in International Journal of Research and Development in Pharmacy & Life Sciences.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Research and Development in Pharmacy & Life Sciences
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Dr. Peter Novak”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels